Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Batyl alcohol (1-O-octadecyl-sn-glycerol) is a naturally occurring 1-O-alkylglycerol found in marine organisms, such as shark liver oil, and soft corals. It serves as a critical metabolic precursor in the biosynthesis of ether-linked phospholipids, specifically plasmalogens. Because batyl alcohol contains a pre-formed ether bond, it can bypass the initial peroxisomal enzymatic steps (catalyzed by GNPAT and AGPS) that are often defective in peroxisomal biogenesis disorders. Consequently, it is primarily investigated as a substrate replacement therapy for conditions like Rhizomelic Chondrodysplasia Punctata (RCDP) and Zellweger Spectrum Disorder (ZSD) to restore peripheral plasmalogen levels. Beyond its role in lipid replacement, batyl alcohol has demonstrated experimental potential in attenuating atherosclerosis, improving cardiac conduction in lipid-deficient models, and protecting against radiation-induced bone marrow damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on batyl alcohol.